In January 2020, following the completion of a successful acquisition process, Cobra Biologics became part of the Cognate Bioservices family. In the months since, the teams have been working closely to align operations, evolve joint service offerings and to create a distinctive, new brand identity.
Designed to flow effortlessly across digital and physical channels, the new Cobra and Cognate logos work in synergy with the series of dots representing the dynamic selection of services offered to our clients. Together, we provide the highest quality development and manufacturing services for the cell and gene therapy fields, ranging from early stage development and pre-clinical services to clinical and commercial supply.
Retaining the original red Cobra brand colour, the new logo features a nod to the DNA helix; a product that Cobra has been manufacturing for its clients since 1998. Since then we have expanded our offering to include the production of viral vectors for gene and immunotherapies and microbiota used as live bacterial therapies.
Drawing on a long-standing and robust brand image, Cobra’s well recognised ball iconography has undergone a similar transformation, with a fresh set of graphics to better represent the range of services offered.
In line with the rebrand, Cobra has launched a refreshed website, with updated content, a seamless user experience and modern visual design. Take a look around.
Peter Coleman, CEO of Cobra Biologics, commented: “This fresh, joint branding depicts the strength of our combined organisations within the Advanced Therapies space and is symbolic of what we want to achieve – an innovative and complete offering for the benefit of our clients.”
J. Kelly Ganjei, CEO of Cognate BioServices, commented: “Our new identity is innovative, modern, and professional - words we would use to describe not only our image but also the services we provide to our clients across the globe.”